(4S)-4-乙基-2-恶唑烷酮 | 13896-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4S)-4-乙基-2-恶唑烷酮
• 英文名称: (S)-4-ethyl-2-oxazolidinone
• 英文别名: (S)-4-ethyloxazolidin-2-one；(4S)-4-ethyl-1,3-oxazolidin-2-one
• CAS: 13896-06-5
• 化学式: C₅H₉NO₂
• 分子量: 115.132
• InChiKey: CRHQYASHOICRND-BYPYZUCNSA-N

物化性质

• 沸点：
  298.9±7.0 °C(Predicted)
• 密度：
  1.047±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C，干燥

SDS

Name:	(4S)-4-Ethyl-2-oxazolidinone Material Safety Data Sheet
Synonym:
CAS:	13896-06-5

Section 1 - Chemical Product MSDS Name: (4S)-4-Ethyl-2-oxazolidinone Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
13896-06-5	(4S)-4-Ethyl-2-oxazolidinone		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 13896-06-5: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Powder
Color: white to light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H9NO2
Molecular Weight: 115.13

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 13896-06-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4S)-4-Ethyl-2-oxazolidinone - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 13896-06-5: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 13896-06-5 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 13896-06-5 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 9/20/2004 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4S)-4-乙基-2-恶唑烷酮 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二环己基磷-2,4,6-三异丙基联苯 sodium hydride 、 sodium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成 (S)-3-(3-(4-(1H-1,2,4-triazol-3-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-ethyloxazolidin-2-one
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
  [FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE MTOR

  摘要：

  公式I的化合物：以及其中R1、R2、R2a、R3、n、X和环B具有说明书中给出的含义的盐，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。

  公开号：

  WO2011029027A1
• 作为产物：
  描述：

  (4S,2'S,3'R)-N-(3-acetoxy-2-methylbutanoyl)-4-ethyl-2-oxazolidinone 在 lithium hydroxide 、 双氧水 作用下， 以87%的产率得到(4S)-4-乙基-2-恶唑烷酮
  参考文献：
  名称：

  外消旋助剂：在不对称合成中的应用

  摘要：

  外消旋助剂已成功用于实现不对称合成。外消旋的Evans aldol产品得自具有良好非对映控制性的外消旋酰基恶唑烷酮。外消旋醇醛产物的对映体通过脂肪酶催化的酰化反应拆分。水解得到对映体富集的恶唑烷酮和对映体富集的β-羟基酸。

  DOI：

  10.1016/s0040-4039(02)00722-0

文献信息

• Asymmetric Synthesis of Aminocyclopropanes and<i>N</i>-Cyclopropylamino Alcohols Through Direct Amidocyclopropanation of Alkenes Using Chiral Organozinc Carbenoids
  作者：Guillaume Bégis、David E. Cladingboel、Laure Jerome、William B. Motherwell、Tom D. Sheppard

  DOI：10.1002/ejoc.200801033

  日期：2009.4

  Chiral N-(diethoxymethyl)oxazolidinones, prepared from the corresponding oxazolidinones by heating in triethyl orthoformate can he used as organozinc carbenoid precursors for the direct enantioselective amidocyclopropanation of alkenes. The reaction is successful with it wide range of oxazolidinones and alkenes and proceeds with moderate to excellent, yield and stereoselectivity. In most cases the

  通过在原甲酸三乙酯中加热由相应的恶唑烷酮制备的手性 N-(二乙氧基甲基)恶唑烷酮可用作烯烃的直接对映选择性酰氨基环丙烷化的有机锌卡宾前体。该反应在广泛的恶唑烷酮和烯烃下成功，并以中等至极好的收率和立体选择性进行。在大多数情况下，反式/外置酰氨基-环丙烷产物是有利的，尽管某些环状烯烃如茚有利于内环丙烷的形成。这些产品可以很容易地加工成环丙氨基醇和氨基酸。((C) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
  申请人：INTEGRAL BIOSCIENCES PRIVATE LIMITED

  公开号：US20200206233A1

  公开（公告）日：2020-07-02

  The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本公开涉及一般用于治疗与突变异柠檬酸脱氢酶（mt-IDH）相关的疾病的化合物，特别是突变IDH1酶。具体地，本发明揭示了式（IA）的化合物，该化合物对突变IDH1酶表现出抑制活性。还公开了使用该化合物治疗与突变IDH1酶过度活性相关的疾病的方法。此外，还公开了其用途、药物组合物和试剂盒。
• Modified Mg : Al hydrotalcite in the synthesis of oxazolidin-2-ones
  作者：Agnieszka Cwik、Aliz Fuchs、Zoltán Hell、Ildikó Böjtös、Dóra Halmai、Petra Bombicz

  DOI：10.1039/b418848a

  日期：——

  The modified Mg : Al (3 : 1) hydrotalcite has been found to be an efficient catalyst in the conversion of carbamates into oxazolidin-2-ones under mild reaction conditions. A wide variety of oxazolidin-2-ones were obtained with excellent chemical yield.

  改性Mg : Al（3 : 1）水滑石已被证实是一种高效催化剂，在温和反应条件下能将氨基甲酸酯转化为噁唑烷-2-酮。多种噁唑烷-2-酮以优异的化学产率获得。
• Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors
  作者：Qian Zhao、James R. Manning、James Sutton、Abran Costales、Martin Sendzik、Cynthia M. Shafer、Julian R. Levell、Gang Liu、Thomas Caferro、Young Shin Cho、Mark Palermo、Gregg Chenail、Julia Dooley、Brian Villalba、Ali Farsidjani、Jinyun Chen、Stephanie Dodd、Ty Gould、Guiqing Liang、Kelly Slocum、Minying Pu、Brant Firestone、Joseph Growney、Tycho Heimbach、Raymond Pagliarini

  DOI：10.1021/acsmedchemlett.8b00182

  日期：2018.7.12

  Mutant isocitrate dehydrogenase 1 (IDH1) is an attractive therapeutic target for the treatment of various cancers such as AML, glioma, and glioblastoma. We have evaluated 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors that bind to an allosteric, induced pocket of IDH1R132H. This Letter describes SAR exploration focused on improving both the in vitro and in vivo metabolic stability of

  突变异柠檬酸脱氢酶1（IDH1）是治疗各种癌症（例如AML，神经胶质瘤和胶质母细胞瘤）的有吸引力的治疗靶标。我们已经评估了3-pyrimidin-4-yl-oxazolidin-2-ones作为与IDH1 R132H的变构，诱导口袋结合的突变IDH1抑制剂。这封信描述了针对改善化合物的体外和体内代谢稳定性的SAR探索，从而将19鉴定为有效的和选择性的突变IDH1抑制剂，该IDH1抑制剂已证明在啮齿动物中具有大脑渗透性和出色的口服生物利用度。在临床前患者衍生的IDH1突变异种移植肿瘤模型研究中，19 有效地抑制了生物标记物2-HG的产生。
• Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
  作者：Young Shin Cho、Julian R. Levell、Gang Liu、Thomas Caferro、James Sutton、Cynthia M. Shafer、Abran Costales、James R. Manning、Qian Zhao、Martin Sendzik、Michael Shultz、Gregg Chenail、Julia Dooley、Brian Villalba、Ali Farsidjani、Jinyun Chen、Raviraj Kulathila、Xiaoling Xie、Stephanie Dodd、Ty Gould、Guiqing Liang、Tycho Heimbach、Kelly Slocum、Brant Firestone、Minying Pu、Raymond Pagliarini、Joseph D. Growney

  DOI：10.1021/acsmedchemlett.7b00342

  日期：2017.10.12

  Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg132. Having identified an allosteric, induced pocket of IDH1R132H, we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors for in vivo modulation of 2-HG production and potential brain penetration. We report here optimization efforts toward the

  突变IDH1的抑制作用正在临床上评估为Arg 132处具有热点突变的各种癌症的有前途的治疗选择。确定了IDH1 R132H的变构，诱导口袋后，我们探索了3-嘧啶-4-基-恶唑烷-2-酮作为IDH1突变体抑制剂，用于体内调节2-HG的产生和潜在的脑渗透。我们在这里报告优化工作，以鉴定临床候选者IDH305（13），这是一种有效且选择性的突变体IDH1抑制剂，已在啮齿动物中证明了其对大脑的暴露。该化合物在临床上的临床前表征患者体内IDH1突变异种移植肿瘤模型中2-HG降低与疗效的相关性。IDH305（13）已进入用于治疗具有IDH1突变的癌症的人类临床试验。

表征谱图